Jump to content

Barry Gusterson

Add links
From Wikipedia, the free encyclopedia
Barry Austin Gusterson
BSc, BDS, MBBS (Hons), FRCPath, PhD
Born (1946-10-24) 24 October 1946 (age 77)[3]
Alma materRoyal Dental Hospital, St Bartholomew's Hospital and Institute of Cancer Research[3]
Known forInitiating the Toby Robins Cancer Research Centre in London [4] and the Wolfson Wohl Cancer Centre in Glasgow.[5][6] Work on EGFR in head and neck cancer [7][8] and studies of HER2 in breast cancer[9] and in human breast development[10][11]
Spouse
Ann Josephine Davies
​
​
(m. 1972)​
[3]
Awards
  • Oakley Lecturer (1985)[1]
  • Doniach Lecturer (2009)[2]
Scientific career
FieldsPathology, Cancer
Institutions
Thesis In Vitro Study of Tumour Associated Opiate Receptors and Tumour Derived Opioid Activity [3]  (1980)

Barry Austin Gusterson (born 24 October 1946) [3] is an Emeritus Professor of Pathology at the University of Glasgow (retired 2010). He was previously Professor of Pathology and Head of the Section of Molecular Pathology at the Institute of Cancer Research in London, and Founding Director of the Toby Robins Breakthrough Breast Cancer Research Centre [4][12][13] (re-named the Toby Robins Breast Cancer Now Research Centre).[14] In 2000-2010 he was Professor of Pathology in Glasgow and was the project lead responsible for building the Wolfson Wohl Cancer Centre.[5][6] He is known for his research on EGFR in head and neck cancer,[7][8] and HER2 in breast cancer [9] and breast development.[10][11]

Education[edit]

Gusterson was educated at Colchester Royal Grammar School[15] and obtained a BSc in Physiology at St Bartholomew’s Hospital. He then obtained a dental degree at the Royal Dental Hospital and a medical degree at St Bartholomew’s Hospital. Whilst at the Institute of Cancer Research and Royal Marsden Hospital he obtained a PhD and an MRCPath.[3]

Career[edit]

Gusterson held posts in medicine and surgery at St Bartholomew’s Hospital and the Royal Devon and Exeter Hospital and was appointed as Professor of Histopathology at the Institute of Cancer Research and Consultant at the Royal Marsden Hospital in 1986. Whilst at the Institute he held a number of senior positions, including Chairman of the Section of Cell Biology and Experimental Pathology and as a Director on the Institute Governing body.[16] He initiated the concept to build the first dedicated breast cancer research centre and was appointed Founding Director of the Toby Robins, Breakthrough Breast Cancer Research Centre in 1998.[4][12][13] His contribution was acknowledged in a Woman’s Hour survey published in the Radio Times in 1996 – ‘top 50 men that women rate’.[17] In 2000 he moved to Glasgow University, where he held a number of positions as Professor of Pathology, and Head of Forensic Science and Medicine, which won an £18.5 M contract from the Crown Office in 2006.[18] Alongside this, he initiated and was Director of the Glasgow Biobank.[5] As Associate Dean for Research in the Medical Faculty and Head of Cancer Sciences he restructured Cancer Sciences. Gusterson chaired the pan-Glasgow pathology Committee that resulted in the unification of all pathology departments across Glasgow and Clyde into a new purpose built building at the Southern General Hospital.[5] In his role as Project Lead, Gusterson was responsible for the building of the Wolfson Wohl Cancer Centre at the Garscube Estate.[5][8][19][20] The two cancer centres initiated by Gusterson were both developed as major fund-raising projects, in which he played a key role as the clinical lead. Gusterson retired in 2011 and became a Director of Moorfield’s Eye Charity [21] and a member of Council for St George's, University of London.[22]

Research[edit]

Human Squamous Cell Carcinomas and Skin

Gusterson has 324 cited publications in Semantic Scholar [23] and 302 in Research Gate[24]

Gusterson’s early work focused on in vitro studies of differentiation of human oral mucosa, skin and squamous cell carcinomas of the head and neck.[25][26] This led to the demonstration of the normal human tissue distribution[27] and overexpression and amplification of the Epidermal Growth Factor Receptors (EGFR) as a feature of squamous cell carcinomas.[7][8] EGFR is now a target for therapy in Head and Neck cancer, but with limited success.[28] Later studies with Tim Crook and others demonstrated the high expression of p53 in head and neck cancer[29] and mutations in BRCA1 and BRCA2 breast cancers.[30][31]

The differentiated normal skin in vitro was used for human skin grafts in burns patients.[32][33][34]

Breast Cancer and Normal Breast Development

Work was mainly based on clinico-pathological studies of human breast cancer and normal breast development. Working as Director of Pathology for the International Breast Cancer Study Group (IBCSG) a BioBank was established for international clinical trials [35] and a Translational Research Working Group[36] to assess research proposals which Gusterson chaired. This collaboration resulted in numerous publications, including the demonstration of c-erbB-2 (HER2) overexpression as a prognostic indicator in breast cancer [9] and suggested a cut point to define patients that would later benefit from Herceptin.[37] Interpretation of the molecular classifications of breast cancer in the context of the normal lineages in the breast gave insights into the limitations of these new technologies.[38][39][40] Work on human breast development described the cell types involved in differentiation of the human breast and their biological significance.[41][42][43][44] Gusterson is also know as an expert in the pathology of animal models of human breast cancer[45] and studies on the biology of involution.[46] With Beatrice Howard the locus was defined for breast development in the mouse mammary gland.[47][48]

Human Sarcomas

Collaborations with Janet Shipley and Colin Cooper resulted in the identification of translocations and genes in a number of soft tissue sarcomas.[49][50][51][52]

Notes[edit]

  1. ^ "Oakley Lecture". www.pathsoc.org. Pathological Society. Retrieved 9 July 2024.
  2. ^ "Doniach Lecture". www.pathsoc.org. Pathological Society. Retrieved 9 July 2024.
  3. ^ a b c d e f g "Gusterson, Prof. Barry Austin". Who's Who. Vol. 2024 (online Oxford University Press ed.). Oxford: A & C Black. (Subscription or UK public library membership required.)
  4. ^ a b c "Breakthrough Breast Cancer". Wikipedia, The Free Encyclopedia. Retrieved 9 July 2024.
  5. ^ a b c d e "A Significant Medical History > 20th Century > 1948-2018 > Pathology". University of Glasgow. Retrieved 9 July 2024.
  6. ^ a b "Huge Boost for the Beatson Pebble Appeal", University of Glasgow - University News, 26 March 2009, retrieved 9 July 2024
  7. ^ a b c Cowley, G. P.; Smith, J. A.; Gusterson, B. A. (1986). "Increased EGF receptors on human squamous carcinoma cell lines". British Journal of Cancer. 53 (2): 223–229. doi:10.1038/bjc.1986.39. PMC 2001344. PMID 2420349.
  8. ^ a b c d Ozanne, B.; Richards, C. S.; Hendler, F.; Burns, D.; Gusterson, B. A. (1986). "Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas". The Journal of Pathology. 149 (1): 9–14. doi:10.1002/path.1711490104. PMID 2425067.
  9. ^ a b c Gusterson, B .A.; Gelber, R. D.; Goldhirsch, A.; Price, K. N.; Säve-Söderborgh, J.; Anbazhagan, R.; Styles, J.; Rudenstam, C. M.; Golouh, R.; Reed, R. (1992). "Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group". Journal of Clinical Oncology. 10 (7): 1049–1056. doi:10.1200/JCO.1992.10.7.1049. PMID 1351538.
  10. ^ a b Anbazhagan, R.; Osin, P. P.; Bartkova, J.; Nathan, B.; Lane, E. B.; Gusterson, B. A. (1998). "The development of epithelial phenotypes in the human fetal and infant breast". The Journal of Pathology. 184 (2): 197–206. doi:10.1002/(SICI)1096-9896(199802)184:2<197::AID-PATH992>3.0.CO;2-J. PMID 9602712.
  11. ^ a b Howard, B. A.; Gusterson, B. A. (2000). "Human breast development". Journal of Mammary Gland Biology and Neoplasia. 5 (2): 119–137. doi:10.1023/a:1026487120779. PMID 11149569.
  12. ^ a b "Breast Cancer Now Toby Robins Research Centre". www.icr.ac.uk. The Institute of Cancer Research. Retrieved 11 July 2024.
  13. ^ a b "Institute of Cancer Research opens new Fulham Road Labs". www.icr.ac.uk. The Institute of Cancer Research. Retrieved 11 July 2024.
  14. ^ "Breast Cancer Now". Wikipedia, The Free Encyclopedia. Retrieved 11 July 2024.
  15. ^ "People educated at Colchester Royal Grammar School". Wikipedia, The Free Encyclopedia. Retrieved 11 July 2024.
  16. ^ "Barry Austin GUSTERSON - Institute of Cancer Research". Companies House. Retrieved 12 July 2024.
  17. ^ "Worlds fifty most desirable men by the listeners of Woman's Hour", Radio Times, 5–11 October 1996
  18. ^ "Forensics contract for Glasgow University". The Herald. Glasgow. 29 November 2006. Retrieved 12 July 2024.
  19. ^ "24 hours a day every day in the west of Scotland ... 54 people are told they have cancer". Glasgow Times. Glasgow. 1 April 2009. Retrieved 12 July 2024.
  20. ^ "Beatson Pebble Appeal nears completion". Glasgow Guardian. Glasgow. 15 January 2011. Retrieved 12 July 2024.
  21. ^ "Barry Austin GUSTERSON - Moorfields Eye Charity". Companies House. Retrieved 12 July 2024.
  22. ^ "St George's University of London - Council Minutes - 16 December 2014" (PDF). St George's University of London. 16 December 2014. Retrieved 12 July 2024.
  23. ^ "B. Gusterson Semantic Scholar Publications list". www.semanticscholar.org. Retrieved 12 July 2024.
  24. ^ "Barry A. Gusterson ResearchGate". www.researchgate.net. Retrieved 12 July 2024.
  25. ^ Knight, J.; Gusterson, B. A.; Cowley, G.; Monaghan, P. (1984). "Differentiation of normal and malignant human squamous epithelium in vivo and in vitro: a morphologic study". Ultrastructural Pathology. 7 (2–3): 133–141. doi:10.3109/01913128409141470. PMID 6085428.
  26. ^ Cowley, G.; Gusterson, B.; Knight, J. (1983). "Growth in agar and tumor formation in immunologically incompetent mice as criteria for keratinocyte transformation". Cancer Letters. 21 (1): 95–104. doi:10.1016/0304-3835(83)90088-5. PMID 6640518.
  27. ^ Gusterson, B.; Cowley, G.; Smith, J. A.; Ozanne, B. (1984). "Cellular localisation of human epidermal growth factor receptor". Cell Biology International Reports. 8 (8): 649–658. doi:10.1016/0309-1651(84)90045-6 (inactive 2024-07-12). PMID 6090028.{{cite journal}}: CS1 maint: DOI inactive as of July 2024 (link)
  28. ^ Gusterson, B. A.; Hunter, K. D. (2009). "Should we be surprised at the paucity of response to EGFR inhibitors?". The Lancet. Oncology. 10 (5): 522–527. doi:10.1016/S1470-2045(09)70034-8. PMID 19410197.
  29. ^ Gusterson, B. A.; Anbazhagan, R.; Warren, W.; Midgely, C.; Lane, D. P.; O'Hare, M.; Stamps, A.; Carter, R.; Jayatilake, H. (1991). "Expression of p53 in premalignant and malignant squamous epithelium". Oncogene. 6 (10): 1785–1789. PMID 1717923.
  30. ^ Crook, T.; Crossland, S.; Crompton, M. R.; Osin, P.; Gusterson, B. A. (1997). "p53 mutations in BRCA1-associated familial breast cancer". Lancet (London, England). 350 (9078): 638–639. doi:10.1016/S0140-6736(05)63327-2. PMID 9288052.
  31. ^ Crook, T.; Brooks, L. A.; Crossland, S.; Osin, P.; Barker, K. T.; Waller, J.; Philp, E.; Smith, P. D.; Yulug, I.; Peto, J.; Parker, G.; Allday, M. J.; Crompton, M. R.; Gusterson, B. A. (1998). "p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours". Oncogene. 17 (13): 1681–1689. doi:10.1038/sj.onc.1202106. PMID 9796697.
  32. ^ Clarke, J. A.; Burt, A. M.; Eldad, A.; Gusterson, B. A. (1986). "Cultured skin for burn injury". Lancet (London, England). 2 (8510): 809. doi:10.1016/s0140-6736(86)90326-0. PMID 2876258.
  33. ^ Eldad, A.; Burt, A.; Clarke, J. A.; Gusterson, B. (1987). "Cultured epithelium as a skin substitute". Burns, Including Thermal Injury. 13 (3): 173–180. doi:10.1016/0305-4179(87)90161-6. PMID 3300888.
  34. ^ Burt, A. M.; Pallett, C. D.; Sloane, J. P.; O'Hare, M. J.; Schafler, K. F.; Yardeni, P.; Eldad, A.; Clarke, J. A.; Gusterson, B. A. (1989). "Survival of cultured allografts in patients with burns assessed with probe specific for Y chromosome". BMJ (Clinical Research Ed.). 298 (6678): 915–917. doi:10.1136/bmj.298.6678.915. PMC 1836188. PMID 2470446.
  35. ^ "International Breast Cancer Study Group BioBank". www.ibcsg.org. IBCSG. Retrieved 12 July 2024.
  36. ^ "IBCSG Translational Research Working Group". www.ibcsg.org. IBCSG. Retrieved 12 July 2024.
  37. ^ Gusterson, B. A. (1992). "Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression". European Journal of Cancer (Oxford, England : 1990). 28 (1): 263–267. doi:10.1016/0959-8049(92)90429-6. PMID 1348953.
  38. ^ Gusterson, B. A.; Ross, D. T.; Heath, V. J.; Stein, T. (2005). "Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer". Breast Cancer Research : BCR. 7 (4): 143–148. doi:10.1186/bcr1041. PMC 1175069. PMID 15987465.
  39. ^ Gusterson, B. (2009). "Do 'basal-like' breast cancers really exist?". Nature Reviews. Cancer. 9 (2): 128–134. doi:10.1038/nrc2571. PMID 19132008.
  40. ^ Gusterson, B.; Eaves, C. J. (2018). "Basal-like Breast Cancers: From Pathology to Biology and Back Again". Stem Cell Reports. 10 (6): 1676–1686. doi:10.1016/j.stemcr.2018.04.023. PMC 6117459. PMID 29874626.
  41. ^ Anbazhagan, R.; Osin, P. P.; Bartkova, J.; Nathan, B.; Lane, E. B.; Gusterson, B. A. (1998). "The development of epithelial phenotypes in the human fetal and infant breast". The Journal of Pathology. 184 (2): 197–206. doi:10.1002/(SICI)1096-9896(199802)184:2<197::AID-PATH992>3.0.CO;2-J. PMID 9602712.
  42. ^ Anbazhagan, R.; Bartek, J.; Monaghan, P.; Gusterson, B. A. (1991). "Growth and development of the human infant breast". The American Journal of Anatomy. 192 (4): 407–417. doi:10.1002/aja.1001920408. PMID 1781450.
  43. ^ Atherton, A. J.; Anbazhagan, R.; Monaghan, P.; Bartek, J.; Gusterson, B. A. (1994). "Immunolocalisation of cell surface peptidases in the developing human breast". Differentiation; Research in Biological Diversity. 56 (1–2): 101–106. doi:10.1046/j.1432-0436.1994.56120101.x. PMID 7913070.
  44. ^ Atherton, A. J.; Warburton, M. J.; O'Hare, M. J.; Monaghan, P.; Schuppan, D.; Gusterson, B. A. (1998). "Differential expression of type XIV collagen/undulin by human mammary gland intralobular and interlobular fibroblasts". Cell and Tissue Research. 291 (3): 507–511. doi:10.1007/s004410051020. PMID 9477307.
  45. ^ Cardiff, R. D.; Anver, M. R.; Gusterson, B. A.; Hennighausen, L.; Jensen, R. A.; Merino, H. J.; Rehm, S.; Russo, J.; Tavassoli, F. A.; Wakefield, L. M.; Ward, J. M.; Green, J. E. (2000). "The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting". Oncogene. 19 (8): 968–988. doi:10.1038/sj.onc.1203277. PMID 10713680.
  46. ^ Stein, T.; Salomonis, N.; Gusterson, B. A. (2007). "Mammary gland involution as a multi-step process". Journal of Mammary Gland Biology and Neoplasia. 12 (1): 25–35. doi:10.1007/s10911-007-9035-7. PMID 17431797.
  47. ^ Howard, B. A.; Gusterson, B. A. (2000). "The characterization of a mouse mutant that displays abnormal mammary gland development". Mammalian Genome : Official Journal of the International Mammalian Genome Society. 11 (3): 234–237. doi:10.1007/s003350010043. PMID 10723730.
  48. ^ Howard, B. A.; Gusterson, B. A. (2000). "Mammary gland patterning in the AXB/BXA recombinant inbred strains of mouse". Mechanisms of Development. 91 (1–2): 305–309. doi:10.1016/s0925-4773(99)00268-3. PMID 10704854.
  49. ^ Shipley, J.; Crew, J.; Gusterson, B. (1993). "The molecular biology of soft tissue sarcomas". European Journal of Cancer (Oxford, England : 1990). 29A (14): 2054–2058. doi:10.1016/0959-8049(93)90470-z. PMID 8280501.
  50. ^ Gusterson, B.; Shipley, J.; Crew, J. (1994). "Application of molecular genetics and cytogenetics to breast cancer and soft tissue sarcomas". Annals of Oncology : Official Journal of the European Society for Medical Oncology. 5 suppl 4: 17–23. doi:10.1093/annonc/5.suppl_4.s17. PMID 8060893.
  51. ^ Clark, J.; Rocques, P. J.; Crew, A. J.; Gill, S.; Shipley, J.; Chan, A. M.; Gusterson, B. A.; Cooper, C. S. (1994). "Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma". Nature Genetics. 7 (4): 502–508. doi:10.1038/ng0894-502. PMID 7951320.
  52. ^ Crew, A. J.; Clark, J.; Fisher, C.; Gill, S.; Grimer, R.; Chand, A.; Shipley, J.; Gusterson, B. A.; Cooper, C.S. (1995). "Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma". The EMBO Journal. 14 (10): 2333–2340. doi:10.1002/j.1460-2075.1995.tb07228.x. PMC 398342. PMID 7539744.

External links[edit]

  • Prof. Barry Gusterson, Honorary Senior Research Fellow at the University of Glasgow, Cancer Sciences, Pathology and Gene Regulation Research department.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Barry_Gusterson&oldid=1234167987"